Therapeutic indications and metabolic effects of metreleptin in patients with lipodystrophy syndromes: Real-life experience from a national reference network.


Journal

Diabetes, obesity & metabolism
ISSN: 1463-1326
Titre abrégé: Diabetes Obes Metab
Pays: England
ID NLM: 100883645

Informations de publication

Date de publication:
08 2022
Historique:
revised: 05 04 2022
received: 15 02 2022
accepted: 18 04 2022
pubmed: 22 4 2022
medline: 9 7 2022
entrez: 21 4 2022
Statut: ppublish

Résumé

To describe baseline characteristics and follow-up data in patients with lipodystrophy syndromes treated with metreleptin in a national reference network, in a real-life setting. Clinical and metabolic data from patients receiving metreleptin in France were retrospectively collected, at baseline, at 1 year and at the latest follow-up during treatment. Forty-seven patients with lipodystrophy including generalized lipodystrophy (GLD; n = 28) and partial lipodystrophy (PLD; n = 19) received metreleptin over the last decade. At baseline, the median (interquartile range [IQR]) patient age was 29.3 (16.6-47.6) years, body mass index was 23.8 (21.2-25.7) kg/m In this real-life setting study, metabolic outcomes are improved by metreleptin therapy in patients with GLD. The therapeutic indication for metreleptin needs to be clarified in patients with PLD.

Identifiants

pubmed: 35445532
doi: 10.1111/dom.14726
pmc: PMC9541305
doi:

Substances chimiques

Leptin 0
metreleptin TL60C27RLH

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1565-1577

Informations de copyright

© 2022 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.

Références

Presse Med. 2021 Nov;50(3):104071
pubmed: 34610417
Pediatrics. 2004 Aug;114(2 Suppl 4th Report):555-76
pubmed: 15286277
J Diabetes Metab. 2016 Mar;7(3):
pubmed: 27642538
J Clin Endocrinol Metab. 2012 Mar;97(3):785-92
pubmed: 22170723
J Clin Endocrinol Metab. 2015 May;100(5):1802-10
pubmed: 25734254
Diabetes Obes Metab. 2022 Aug;24(8):1565-1577
pubmed: 35445532
Diabetes. 2002 Sep;51(9):2727-33
pubmed: 12196465
Diabetes Obes Metab. 2016 Jul;18(7):693-7
pubmed: 26584826
Diabetes. 2016 Aug;65(8):2179-86
pubmed: 27207511
J Endocr Soc. 2021 Feb 16;5(4):bvab019
pubmed: 33817539
Endocrinol Diabetes Metab Case Rep. 2021 Sep 01;2021:
pubmed: 34515658
Metabolism. 2007 Apr;56(4):508-16
pubmed: 17379009
Front Endocrinol (Lausanne). 2021 Jun 08;12:684182
pubmed: 34168618
Front Endocrinol (Lausanne). 2021 May 31;12:690996
pubmed: 34135866
Endocrine. 2015 May;49(1):139-47
pubmed: 25367549
Mol Metab. 2021 Apr;46:101102
pubmed: 33068776
Orphanet J Rare Dis. 2019 Jul 12;14(1):177
pubmed: 31300002
Diabetes Metab Syndr Obes. 2017 Sep 13;10:375-383
pubmed: 29066925
Front Endocrinol (Lausanne). 2019 Apr 12;10:155
pubmed: 31031702
Endocrine. 2019 Jun;64(3):500-511
pubmed: 30805888
Diabetologia. 2010 Jan;53(1):27-35
pubmed: 19727665
Value Health. 2021 Jan;24(1):112-115
pubmed: 33431143
Diabetes. 2001 Jun;50(6):1440-8
pubmed: 11375346
J Clin Endocrinol Metab. 2019 Apr 16;:
pubmed: 30990519
Curr Med Res Opin. 2021 Nov;37(11):1881-1889
pubmed: 34490811
Ann Endocrinol (Paris). 2020 Feb;81(1):51-60
pubmed: 31982105
J Clin Invest. 2002 May;109(10):1345-50
pubmed: 12021250
Endocrine. 2018 Jun;60(3):479-489
pubmed: 29644599
N Engl J Med. 2002 Feb 21;346(8):570-8
pubmed: 11856796
J Clin Endocrinol Metab. 2016 Dec;101(12):4500-4511
pubmed: 27710244
J Clin Endocrinol Metab. 2012 Oct;97(10):3663-71
pubmed: 22872692
J Clin Endocrinol Metab. 2021 Sep 27;106(10):e4163-e4178
pubmed: 33890058
J Clin Endocrinol Metab. 2022 Mar 24;107(4):e1739-e1751
pubmed: 34677608
Natl Med J India. 2020 Sep-Oct;33(5):278-280
pubmed: 34213454
Diabetes. 2020 Feb;69(2):249-258
pubmed: 31836692
Eur J Endocrinol. 2010 Jun;162(6):1083-91
pubmed: 20236991
J Med Case Rep. 2017 Jan 13;11(1):12
pubmed: 28086952
J Clin Invest. 2018 Aug 1;128(8):3504-3516
pubmed: 29723161
Presse Med. 2021 Nov;50(3):104070
pubmed: 34571177
Orphanet J Rare Dis. 2020 Jan 15;15(1):17
pubmed: 31941540
Diabet Med. 2017 Dec;34(12):1792-1794
pubmed: 29044799
Endocr Pract. 2011 Nov-Dec;17(6):922-32
pubmed: 22068254

Auteurs

Héléna Mosbah (H)

Endocrinology Department, Assistance Publique-Hôpitaux de Paris (AP-HP), Saint-Antoine University Hospital, National Reference Centre for Rare Diseases of Insulin Secretion and Insulin Sensitivity (PRISIS), Paris, France.
Sorbonne University, Inserm UMR_S 938, Saint-Antoine Research Centre, Cardiometabolism and Nutrition University Hospital Institute (ICAN), Paris, France.

Marie-Christine Vantyghem (MC)

Department of Endocrinology, Diabetology and Metabolism, Lille University Hospital; University of Lille, INSERM U1190, European Genomic Institute for Diabetes, Lille, France.

Estelle Nobécourt (E)

Department of Endocrinology, Diabetology and Metabolism, La Réunion University Hospital, Saint Pierre de la Réunion, France.

Fabrizio Andreelli (F)

AP-HP, Pitié-Salpêtrière University Hospital, Department of Diabetology; Sorbonne University, INSERM, Nutrition and Obesity: systemic approaches « NutriOmics », Paris, France.

Francoise Archambeaud (F)

Department of Endocrinology, Diabetology and Metabolism, Dupuytren University Hospital, Limoges, France.

Elise Bismuth (E)

AP-HP, Robert-Debré University Hospital, Department of Paediatric Endocrinology, Diabetology and Metabolism, University of Paris, Paris, France.

Claire Briet (C)

Department of Endocrinology, Diabetology and Metabolism, Angers University Hospital, Laboratory MITOVASC, UMR CNRS 6015, INSERM 1083, Angers, France.

Maryse Cartigny (M)

Reference Centre for Rare Diseases of Genital Development DEVGEN, Endocrinology Unit, Diabetology and Paediatric Gynecology Department, Lille University Hospital, Lille, France.

Benjamin Chevalier (B)

Department of Endocrinology, Diabetology and Metabolism, Lille University Hospital; University of Lille, INSERM U1190, European Genomic Institute for Diabetes, Lille, France.

Bruno Donadille (B)

Endocrinology Department, Assistance Publique-Hôpitaux de Paris (AP-HP), Saint-Antoine University Hospital, National Reference Centre for Rare Diseases of Insulin Secretion and Insulin Sensitivity (PRISIS), Paris, France.
Sorbonne University, Inserm UMR_S 938, Saint-Antoine Research Centre, Cardiometabolism and Nutrition University Hospital Institute (ICAN), Paris, France.

Anne Daguenel (A)

Department of Pharmacy, AP-HP, Saint-Antoine University Hospital, Paris, France.

Mathilde Fichet (M)

Department of Endocrinology, Diabetology and Metabolism, Rennes University Hospital, Rennes, France.

Jean-François Gautier (JF)

Department of Endocrinology, Diabetology and Metabolism, AP-HP, Lariboisière University Hospital, Paris, France.

Sonja Janmaat (S)

Endocrinology Department, Assistance Publique-Hôpitaux de Paris (AP-HP), Saint-Antoine University Hospital, National Reference Centre for Rare Diseases of Insulin Secretion and Insulin Sensitivity (PRISIS), Paris, France.
Sorbonne University, Inserm UMR_S 938, Saint-Antoine Research Centre, Cardiometabolism and Nutrition University Hospital Institute (ICAN), Paris, France.

Isabelle Jéru (I)

Endocrinology Department, Assistance Publique-Hôpitaux de Paris (AP-HP), Saint-Antoine University Hospital, National Reference Centre for Rare Diseases of Insulin Secretion and Insulin Sensitivity (PRISIS), Paris, France.
Sorbonne University, Inserm UMR_S 938, Saint-Antoine Research Centre, Cardiometabolism and Nutrition University Hospital Institute (ICAN), Paris, France.

Carole Legagneur (C)

Department of Paediatric Endocrinology, Diabetology and Metabolism, University Hospital Brabois-Vandoeuvre lès Nancy, Vandoeuvre lès Nancy, France.

Lysiane Leguier (L)

Department of Endocrinology, Diabetology and Metabolism, Lille University Hospital; University of Lille, INSERM U1190, European Genomic Institute for Diabetes, Lille, France.

Julie Maitre (J)

Department of Paediatrics and Endocrinology, Diabetology and Metabolism, Orléans Hospital, Orléans, France.

Elise Mongeois (E)

Department of Paediatrics and Endocrinology, Diabetology and Metabolism, Orléans Hospital, Orléans, France.

Christine Poitou (C)

Nutrition Department, Sorbonne University/INSERM, Research Unit: Nutrition and Obesity; Systemic Approaches (NutriOmics), AP-HP, Pitié-Salpêtrière University Hospital, Reference Centre for Rare Diseases PRADORT (PRADer-Willi Syndrome and other Rare Obesities with Eating Disorders), Paris, France.

Eric Renard (E)

Department of Endocrinology, Diabetes and Nutrition, Montpellier University Hospital; Clinical Investigation Centre INSERM1411; Institute of Functional Genomics, CNRS, INSERM, University of Montpellier, Montpellier, France.

Yves Reznik (Y)

Department of Endocrinology, Diabetology and Metabolism, Côte de Nacre University Hospital, Caen, France.

Anne Spiteri (A)

Department of Endocrinology, Diabetology and Metabolism, Grenoble University Hospital, Grenoble, France.

Florence Travert (F)

Department of Diabetology and Metabolism, AP-HP, Bichat University Hospital, Paris, France.

Bruno Vergès (B)

Department of Endocrinology, Diabetology and Metabolism, Bocage University Hospital, Dijon, France.

Jamila Zammouri (J)

Sorbonne University, Inserm UMR_S 938, Saint-Antoine Research Centre, Cardiometabolism and Nutrition University Hospital Institute (ICAN), Paris, France.
AP-HP, Robert-Debré University Hospital, Department of Paediatric Endocrinology, Diabetology and Metabolism, University of Paris, Paris, France.

Corinne Vigouroux (C)

Endocrinology Department, Assistance Publique-Hôpitaux de Paris (AP-HP), Saint-Antoine University Hospital, National Reference Centre for Rare Diseases of Insulin Secretion and Insulin Sensitivity (PRISIS), Paris, France.
Sorbonne University, Inserm UMR_S 938, Saint-Antoine Research Centre, Cardiometabolism and Nutrition University Hospital Institute (ICAN), Paris, France.

Camille Vatier (C)

Endocrinology Department, Assistance Publique-Hôpitaux de Paris (AP-HP), Saint-Antoine University Hospital, National Reference Centre for Rare Diseases of Insulin Secretion and Insulin Sensitivity (PRISIS), Paris, France.
Sorbonne University, Inserm UMR_S 938, Saint-Antoine Research Centre, Cardiometabolism and Nutrition University Hospital Institute (ICAN), Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH